Therefore, in this study, we aimed to comprehensively analyze how in our opinion promising biomarker HE4 could be influenced by the administration of CFTR modulators, since the pathogenesis of upregulated HE4 expression in CF is not fully understood. This evidence concerns the gene CFTR and cystic fibrosis.